SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes
NCT ID: NCT07272057
Last Updated: 2025-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
200 participants
INTERVENTIONAL
2025-12-07
2026-11-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and diabetes. It will also check if these drugs are safe for these patients. The main questions it aims to answer are:
* Does adding an SGLT2 inhibitor to standard cancer treatment improve survival?
* Does it cause more or fewer cardiovascular toxicity?
* What side effects do participants experience? Researchers will compare a group taking an SGLT2 inhibitor to a group not taking SGLT2 inhibitor to see if the drug works.
Participants will:
* Be adults diagnosed with advanced lung cancer and type 2 diabetes.
* Take either the SGLT2 inhibitor pill or other hypoglycemic drugs once a day alongside their cancer treatment.
* Undergo regular clinical visits for monitoring, laboratory tests, and imaging studies
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
NCT06688123
Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy
NCT01240759
Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes
NCT02605772
Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients
NCT05914857
SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
NCT05782192
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
treatment group
On the basis of standard cancer treatment, take dapagliflozin for at least three months, once a day, 10 mg each time.
SGLT-2 inhibitor
SGLT2 inhibitors used for patients with lung cancer and diabetes
control group
Based on the standard treatment for tumors, for the treatment of diabetes, no dapagliflozin has been taken.
Sham (No Treatment)
SGLT2 inhibitors are not used for patients with lung cancer and diabetes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SGLT-2 inhibitor
SGLT2 inhibitors used for patients with lung cancer and diabetes
Sham (No Treatment)
SGLT2 inhibitors are not used for patients with lung cancer and diabetes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Chest Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Liang Zhao
Dr
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SLC-DO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.